TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8934869

Group type: EXPERIMENTAL
Intervention: High Reprimand Consistency with Attend response
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low Reprimand Consistency with Attend response
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High Reprimand Consistency with Ignore response
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low Reprimand Consistency with Ignore response
Number of subjects: 18
Study: 8145392

Group type: EXPERIMENTAL
Intervention: Males spending 7 hours or more outside daily
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Females with 4 or fewer remaining teeth
Number of subjects: 424
Study: 3021500

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg q.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29206774

Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactobacillus-dominant vaginal microbiota
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaginal glycogen, serum estradiol, and estrone
Number of subjects: 30
Study: 27756419

Group type: EXPERIMENTAL
Intervention: Intrathoracic esophagogastric anastomosis (IEA) after MIE
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cervical esophagogastric anastomosis (CEA) after MIE
Number of subjects: 200
Study: 23427974

Group type: EXPERIMENTAL
Intervention: Telemedicine ATLS course
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard on-site ATLS course
Number of subjects: 2
Study: 21342437

Group type: EXPERIMENTAL
Intervention: Zinc oxide and eugenol cement (ZOE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Calen(®) paste thickened with zinc oxide (Calen(®) /ZO)
Number of subjects: 31
Study: 19723986

Group type: EXPERIMENTAL
Intervention: Cruciate-substituting rotating-platform design
Number of subjects: 273

Group type: COMPARATOR
Intervention: Fixed-bearing design with an all-polyethylene tibial component
Number of subjects: 273
Study: 17802785

Group type: EXPERIMENTAL
Intervention: ALL-MB 91
Number of subjects: 713

Group type: COMPARATOR
Intervention: ALL-BFM 90m
Number of subjects: 713
Study: 14631124

Group type: EXPERIMENTAL
Intervention: Combined treatment with azathioprine (AZA) and interferon beta(1a)
Number of subjects: 23
Study: 11396998

Group type: EXPERIMENTAL
Intervention: Filgrastim (recombinant human form of granulocyte colony‐stimulating factor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9407252

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake (CHO) of 10 g.kg‐1 bm during the 22‐hr recovery
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isocaloric diet (CON) with extra protein and fat
Number of subjects: 6
Study: 8498900

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rh‐EPO) therapy
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (no rh‐EPO therapy in the first year)
Number of subjects: 362
Study: 3079056

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Antilymphoblast globulin (ALG) therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study: 28752418

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (120 mg docosahexaenoic acid and 180 mg eicosapentaenoic acid) daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 27626142

Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in emmetropic eyes (EE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in highly myopic eyes (ME)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in both groups (EE and ME)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) during WDT in highly myopic eyes (ME)
Number of subjects: 30
Study: 24942756

Group type: EXPERIMENTAL
Intervention: Irradiated, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐secreting, allogeneic PDAC vaccine (GVAX)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GVAX in combination with low‐dose cyclophosphamide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GVAX
Number of subjects: 39
Study: 22526159

Group type: EXPERIMENTAL
Intervention: Intravenous treosulfan (7,000 mg/m2 on day 1 of a 28-day cycle)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral treosulfan (600 mg/m2 on days 1-28 of a 56-day cycle)
Number of subjects: 51
Study: 20732718

Group type: EXPERIMENTAL
Intervention: MB11 BERAphone
Number of subjects: 54

Group type: COMPARATOR
Intervention: ALGOportable
Number of subjects: 54
Study: 18374336

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and simvastatin
Number of subjects: 125
Study: 15991880

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg following a standard high‐fat content meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Eslicarbazepine acetate 800 mg following 10 hours of fasting
Number of subjects: 12
Study: 12495202

Group type: EXPERIMENTAL
Intervention: Sulfated polysaccharides from red microalgae (topical application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfated polysaccharides from red microalgae (in vitro)
Number of subjects: 0
Study: 10384681

Group type: EXPERIMENTAL
Intervention: SF-36 administered via in-person or telephone interviews
Number of subjects: 31

Group type: COMPARATOR
Intervention: Self-administered SF-36
Number of subjects: 31
Study: 8679062

Group type: EXPERIMENTAL
Intervention: Antidementia drug tacrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADAS-COG total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factor scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated measures ANOVA
Number of subjects: 0
Study: 1678518

Group type: EXPERIMENTAL
Intervention: Minor intervention (single consultation and pamphlet)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Major intervention (extensive interview and follow-up consultations)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 338
Study: 7070885

Group type: EXPERIMENTAL
Intervention: 4 mg albuterol syrup (2 mg/5 ml) four times a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 mg albuterol syrup
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mg albuterol tablets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg albuterol
Number of subjects: 20
Study: 31750709

Group type: EXPERIMENTAL
Intervention: Judgments based on core representations; prompting to consider the entire distribution of others' preferences (Study 10)
Number of subjects: 17594

Group type: EXPERIMENTAL
Intervention: Core representation uniformly positive (Studies 8A-8B)
Number of subjects: 17594

Group type: EXPERIMENTAL
Intervention: Judgments of others' preferences (Studies 9A-9B)
Number of subjects: 17594

Group type: EXPERIMENTAL
Intervention: Measurement of preferences (Study 7)
Number of subjects: 17594

Group type: EXPERIMENTAL
Intervention: General experience representation (Studies 1-5, Study 6)
Number of subjects: 17594
Study: 30831103

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 800 mcg every 3 hours for three doses
Number of subjects: 401

Group type: COMPARATOR
Intervention: Sublingual misoprostol 800 mcg every 3 hours for three doses
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol with additional misoprostol at follow-up
Number of subjects: 401

Group type: COMPARATOR
Intervention: Sublingual misoprostol with additional misoprostol at follow-up
Number of subjects: 401

Group type: COMPARATOR
Intervention: Sublingual misoprostol
Number of subjects: 401
Study: 28724016

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) plus regular care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular programs provided by the institution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group analysis of all participants
Number of subjects: 0
Study: 24740733

Group type: EXPERIMENTAL
Intervention: Benign tumors (n = 13)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Malignant tumors (n = 4)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Benign tumors post-surgery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Malignant tumors post-surgery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall neurophysiological assessments
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Needle EMG, ENG and BR examinations
Number of subjects: 17
Study: 25277158

Group type: EXPERIMENTAL
Intervention: 4-session mother-infant intervention (HUGS: Happiness Understanding Giving and Sharing)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4-session attention placebo playgroup (Playtime)
Number of subjects: 100
Study: 22035285

Group type: EXPERIMENTAL
Intervention: SA and CDP + BPO
Number of subjects: 49

Group type: COMPARATOR
Intervention: CDP + BPO
Number of subjects: 49
Study: 19358928

Group type: EXPERIMENTAL
Intervention: Functional food containing DHA
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Maternal plasma PLs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Maternal RBC PLs
Number of subjects: 59
Study: 17237451

Group type: EXPERIMENTAL
Intervention: Formats with a number (e.g., pie charts, vertical bars, horizontal bars, digits, systematic ovals, random ovals)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Formats with only a scale (e.g., pie charts, random ovals)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Vertical bars with scales
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Foreground and background color variations (black and white vs. blue and yellow; white vs. blue)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Systematic ovals with a scale
Number of subjects: 216
Study: 15281471

Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI, 400 microg every evening (1 puff daily)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fluticasone propionate MDI, two 125-microg puffs twice daily
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fluticasone propionate MDI
Number of subjects: 167
Study: 12045412

Group type: EXPERIMENTAL
Intervention: Various medications for treatment of status asthmaticus; specific drugs, doses, and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination of cost-adding treatments without improved quality of care; specific interventions not available.
Number of subjects: 0
Study: 9471047

Group type: EXPERIMENTAL
Intervention: Spermatic artery ligation (Group I)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Spermatic artery preservation (Group II)
Number of subjects: 75
Study: 9346617

Group type: EXPERIMENTAL
Intervention: Diltiazem (DIL group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nifedipine (NIF group)
Number of subjects: 32
Study: 2172395

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone (168 micrograms twice a day) and oral prednisone (30 mg twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 101432

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0
Study: 31253226

Group type: EXPERIMENTAL
Intervention: Somatostatin combined with pantoprazole
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 82
Study: 28541633

Group type: EXPERIMENTAL
Intervention: Time interval (TI) ≤4 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time interval (TI) >4 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time interval (TI) ≤6 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time interval (TI) >6 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Time interval (TI) >4 weeks in squamous cell carcinoma
Number of subjects: 110

Group type: COMPARATOR
Intervention: Deep stromal invasion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Parametrial involvement (PI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tumor size
Number of subjects: 110
Study: 25728612

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 µg/day
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 24471250

Group type: EXPERIMENTAL
Intervention: Prasugrel (loading dose of 60 mg followed by maintenance dose of 10 mg once daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Clopidogrel (loading dose of 300 mg followed by maintenance dose of 75 mg once daily)
Number of subjects: 210
Study: 21212103

Group type: EXPERIMENTAL
Intervention: High-dose octreotide LAR (60 mg/28 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-frequency octreotide LAR (30 mg/21 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-dose octreotide LAR
Number of subjects: 26
Study: 18217176

Group type: EXPERIMENTAL
Intervention: Pelvic Organ Prolapse Quantification Index (POP-Q-I)
Number of subjects: 50
Study: 17302367

Group type: EXPERIMENTAL
Intervention: LB80380 30 mg once per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LB80380 60 mg once per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LB80380 120 mg once per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LB80380 240 mg once per day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15455897

Group type: EXPERIMENTAL
Intervention: WebSET training tool for lumbar puncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 11097284

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% instilled 15 min prior to surgery
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no brimonidine)
Number of subjects: 123
Study: 8811473

Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of delmopinol hydrochloride applied 2 times a day for 7 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of delmopinol hydrochloride applied on previously placebo-treated surfaces
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 14
Study: 1569229

Group type: EXPERIMENTAL
Intervention: 0.05% delmopinol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.05%, 0.1%, and 0.2% delmopinol
Number of subjects: 64
Study: 4043663

Group type: EXPERIMENTAL
Intervention: Magnesium chloride (12.5 mM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choline chloride (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium (and calcium)
Number of subjects: 0
Study: 31336051

Group type: EXPERIMENTAL
Intervention: Intervention group (5 stretching, 2 dynamic mobility, and 2 balance training exercises during warm-up)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 237
Study: 29454140

Group type: EXPERIMENTAL
Intervention: Group phone conferences (GP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Individual phone calls (IP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 200
Study: 27235114

Group type: EXPERIMENTAL
Intervention: Music therapy intervention group (MTG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Singing group (SG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No-intervention control group (CG)
Number of subjects: 14
Study: 24877181

Group type: EXPERIMENTAL
Intervention: Azacitidine 25-100 mg/m2 SC doses in patients with normal renal function (n=21)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 SC doses for 5 consecutive days in patients with severe renal impairment (n=6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 SC doses (multiple doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Azacitidine in patients with normal renal function (n=6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azacitidine in patients with normal or impaired renal function
Number of subjects: 27
Study: 22338070

Group type: EXPERIMENTAL
Intervention: 10 g whey protein
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 20 g whey protein
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 35 g whey protein
Number of subjects: 33
Study: 19958428

Group type: EXPERIMENTAL
Intervention: Combination of three full‐face IPL treatments and six full‐face topical antioxidant applications (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Three full‐face IPL treatments (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Six weekly full‐face treatments of a pneumatically applied topical polyphenolic antioxidant solution (Group B)
Number of subjects: 30
Study: 17554013

Group type: EXPERIMENTAL
Intervention: Greater temporal distance since the transgression (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective perception of temporal distance (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real temporal distance perception (Experiment 3)
Number of subjects: 0
Study: 15884262

Group type: EXPERIMENTAL
Intervention: GnRH analogue (50 mg oral doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11606512

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9733031

Group type: EXPERIMENTAL
Intervention: Audiotape of the genetic consultation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 115
Study: 8055737

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 1 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 2 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 4 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 1 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 2 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 4 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Transnasal placebo
Number of subjects: 7
Study: 3056221

Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy (streptococcus pyogenes preparation (picibanil) intramuscularly every week, plus either MFC or FME chemotherapy regimen)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Surgery alone (no further anticancer therapy)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy
Number of subjects: 138
Study: 31742465

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (ePTFE) mesh
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other types of mesh (group B)
Number of subjects: 60
Study: 29088393

Group type: EXPERIMENTAL
Intervention: EX+MT+B
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: EX+B
Number of subjects: 300

Group type: COMPARATOR
Intervention: EX
Number of subjects: 300

Group type: COMPARATOR
Intervention: EX+MT
Number of subjects: 300
Study: 28069060

Group type: EXPERIMENTAL
Intervention: Short-stretch, inelastic compression bandage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard wool and crepe bandage
Number of subjects: 50
Study: 26213379

Group type: EXPERIMENTAL
Intervention: Coming Out Proud (COP) program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 126
Study: 23774030

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BTX‐A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB (BTX‐B)
Number of subjects: 16
Study: 21680253

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (to induce pain)
Number of subjects: 9
Study: 17244767

Group type: EXPERIMENTAL
Intervention: Single oral 600-mg dose of cyclosporine with a single 100-mg oral sitagliptin dose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single oral 100-mg sitagliptin dose alone
Number of subjects: 8
Study: 15258553

Group type: EXPERIMENTAL
Intervention: metformin + pioglitazone 30 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: metformin + placebo
Number of subjects: 40
Study: 11832307

Group type: EXPERIMENTAL
Intervention: α-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9427226

Group type: EXPERIMENTAL
Intervention: Diabetic sensorimotor peripheral neuropathy (DSPN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetic autonomic neuropathy (DNA)
Number of subjects: 0
Study: 7851369

Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 45 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 60 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 90 seconds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 90-second test
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of tests
Number of subjects: 8
Study: 2701034

Group type: EXPERIMENTAL
Intervention: Magnetic device therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 58
Study: 786669

Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (oral administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (intravenous administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (oral and iv administration)
Number of subjects: 16
Study: 29722166

Group type: EXPERIMENTAL
Intervention: SRP plus 1% ALN gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SRP plus AV gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: SRP plus placebo gel
Number of subjects: 90
Study: 28746926

Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis
Number of subjects: 18
Study: 25920295

Group type: EXPERIMENTAL
Intervention: Probiotics group (Lactobacillus casei, Shirota strain)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150